SCHEMBL24285966

SCHEMBL24285966

Cc1c(-c2ccc3nc(N)c(C=O)n3c2)ccc2[nH]ncc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 5/20 0.34
▸ PDK1 Q15118 3/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ PDK3 Q15120 1/20 0.34
▸ PDK4 Q16654 1/20 0.34
▸ MAPKAPK2 P49137 1/20 0.33
▸ ESR1 P03372 5/20 0.32
▸ ESR2 Q92731 5/20 0.32
▸ USP7 Q93009 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ METTL3 Q86U44 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ KCNH2 Q12809 1/20 0.30
▸ NT5E P21589 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24286014 0.84 USP7 (0.32) USP7NPC1ALDH1A1RAB9A
SCHEMBL24285963 0.76 MAP4K1 (0.47) MAP4K1
SCHEMBL29537390 0.76 MAP4K1 (0.47) MAP4K1
SCHEMBL24285831 0.74 LRRK2 (0.48) —
SCHEMBL24285948 0.70 MAP3K14 (0.43) ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL24286072 0.70 PIM1 (0.34) USP7NPC1ALDH1A1RAB9A
SCHEMBL24286667 0.70 PRKCZ (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL24286674 0.69 DPP4 (0.40) USP7NPC1ALDH1A1RAB9AFLT1
SCHEMBL24285875 0.68 DHFR (0.37) USP7KDR
SCHEMBL24285859 0.68 CA12 (0.45) NPC1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 MAP4K1 235/4885PDK1 502/4885PDK2 272/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 MAP4K1 235/4885PDK1 502/4885PDK2 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback